For Wide Participation, Preferential For Me/Epp/Mei/Eireli. Items Configured Desert/Failed In Pe S Ics Nº 23, 24 And 27/2023. Abatacept,Acalabrutinib,Acyclovir,Folic Acid,Benralizumab,Buprenorphine,Buprenorphine,Buprenorphine,Ferric Carboxymaltose,Dabrafenib,Dasatinib,Everolimus,Fremanezumab,Goserelin Acetate,Ibrutinib,Liraglutide,Mepolizumab,Mercaptopurine,Mitotane,Nilotinib,Nintedanib,N Iraparib,Olaparib,Olaparib ,Osimertinib,Oxybuprocaine,Ponatinib,Ribociclib,Risankizumab,Romosozumab,Secukinumab,Sulfamethoxazole,Tocilizumab,Tocilizumab,Botulinum Toxin,Ustekinumab,Vemurafenib
|